Src tyrosine kinase has long been implicated in colon cancer but much remains to be learned about its substrates. The nuclear receptor hepatocyte nuclear factor 4α (HNF4α) has just recently been implicated in colon cancer but its role is poorly defined. Here we show that c-Src phosphorylates human HNF4α on three tyrosines in an interdependent and isoform-specific fashion. The initial phosphorylation site is a Tyr residue (Y14) present in the N-terminal A/B domain of P1-but not P2-driven HNF4α. Phospho-Y14 interacts with the Src SH2 domain, leading to the phosphorylation of two additional tyrosines in the ligand binding domain (LBD) in P1-HNF4α. Phosphomimetic mutants in the LBD decrease P1-HNF4α protein stability, nuclear localization and transactivation function. Immunohistochemical analysis of approximately 450 human colon cancer specimens (Stage III) reveals that P1-HNF4α is either lost or localized in the cytoplasm in approximately 80% of tumors, and that staining for active Src correlates with those events in a subset of samples. Finally, three SNPs in the human HNF4α protein, two of which are in the HNF4α F domain that interacts with the Src SH3 domain, increase phosphorylation by Src and decrease HNF4α protein stability and function, suggesting that individuals with those variants may be more susceptible to Src-mediated effects. This newly identified interaction between Src kinase and HNF4α has important implications for colon and other cancers.
Src tyrosine kinase has long been implicated in colon cancer but much remains to be learned about its substrates. The nuclear receptor hepatocyte nuclear factor 4α (HNF4α) has just recently been implicated in colon cancer but its role is poorly defined. Here we show that c-Src phosphorylates human HNF4α on three tyrosines in an interdependent and isoform-specific fashion. The initial phosphorylation site is a Tyr residue (Y14) present in the N-terminal A/B domain of P1-but not P2-driven HNF4α. Phospho-Y14 interacts with the Src SH2 domain, leading to the phosphorylation of two additional tyrosines in the ligand binding domain (LBD) in P1-HNF4α. Phosphomimetic mutants in the LBD decrease P1-HNF4α protein stability, nuclear localization and transactivation function. Immunohistochemical analysis of approximately 450 human colon cancer specimens (Stage III) reveals that P1-HNF4α is either lost or localized in the cytoplasm in approximately 80% of tumors, and that staining for active Src correlates with those events in a subset of samples. Finally, three SNPs in the human HNF4α protein, two of which are in the HNF4α F domain that interacts with the Src SH3 domain, increase phosphorylation by Src and decrease HNF4α protein stability and function, suggesting that individuals with those variants may be more susceptible to Src-mediated effects. This newly identified interaction between Src kinase and HNF4α has important implications for colon and other cancers.
HNF4 isoforms | SH2 SH3 domain | SNP | Src kinase | tyrosine phosphorylation C olon cancer, the third most common malignancy in the United States, is a multifactorial disease that is influenced by both genetics and the environment (1, 2) . c-Src is a nonreceptor tyrosine kinase that is strongly implicated in the development, growth, progression, and metastasis of several human cancers (3) . In colon cancer, Src activation is associated with the early stages (4, 5) as well as progression and metastasis (6) (7) (8) . Despite this long association with colon cancer, much remains to be learned about Src substrates (9) .
Hepatocyte nuclear factor 4alpha (HNF4α) (NR2A1) is a highly conserved member of the nuclear receptor superfamily with a recently identified endogenous ligand (linoleic acid) that binds in a reversible fashion (10, 11) . HNF4α is best known for its role as a master regulator of liver-specific gene expression and as a key player in beta cells of the pancreas where it is mutated in an inherited form of type 2 diabetes (12) (13) (14) . HNF4α is also expressed in kidney, stomach, and intestine; several recent papers also show an important role for HNF4α in the colon (15) (16) (17) (18) (19) (20) . There are two different promoters (P1 and P2) of HNF4A that are utilized in a temporal and tissue-specific fashion (11) (Fig. S1 ). While only P1-driven HNF4α (P1-HNF4α) is expressed in the adult liver, both P1-and P2-driven HNF4α (P2-HNF4α) are expressed in the adult intestine and colon (21, 22) . Expression of P1-HNF4α is decreased in several human cancers including hepatocellular, gastric, renal, and colorectal carcinomas, while the expression of P2-HNF4α is either unchanged or upregulated (22, 23) . However, the mechanism responsible for the differential dysregulation of P1-and P2-HNF4α isoforms is not known. Here we show that Src kinase preferentially phosphorylates P1-HNF4α in vitro and in vivo on multiple residues in a complex fashion, resulting in a loss of function and protein stability of P1-but not P2-HNF4α. We also show that the phosphorylation is influenced by the SH2 and SH3 domains of Src and by SNPs in HNF4α. Finally, we show that increased staining for active Src is associated with a loss of nuclear P1-HNF4α in a sizeable cohort of human colorectal tumors. These findings suggest a unique link between an oncogenic kinase, a potent differentiation factor and human colon cancer.
Results
Src Preferentially Phosphorylates P1-HNF4α Both In Vitro and In Vivo.
An in vitro kinase assay showed that Src phosphorylates full length human P1-HNF4α2 as well as a truncated fragment that corresponds to the N-terminal portion [A/B and DNA binding domain (DBD)] (Fig. S2 A and B) . Since P1-and P2-HNF4α differ by approximately 29 amino acids in the A/B domain (Fig. S1C) , we repeated the kinase assay and found that Src does not appreciably phosphorylate P2-HNF4α8 in vitro (Fig. 1A and Fig. S2G ). Cotransfection of HEK293 cells with constitutively active c-Src (c-Src Y530F) and HNF4α2 also showed in vivo tryosine phosphorylation of P1-HNF4α2 using the phospho-Tyr (pY) specific Ab 4G10; the signal was greatly reduced in cells pretreated with Src inhibitor PP1 (Fig. S2H) . In contrast, the in vivo tyrosine phosphorylation signal of HNF4α8 was also much less than that of HNF4α2, even in the presence of the tyrosine phosphatase inhibitor pervanadate (PV) (Fig. 1B) .
To map Src phosphosites we mutated the two tyrosines in the HNF4α2 A/B domain to Phe (Y6F and Y14F) and found that only the Y14F mutation abolished the in vitro phosphorylation (Fig. S2C) . Mass spectrometric analysis also identified a doubly phosphorylated peptide containing Y277 and Y279 in the ligand binding domain (LBD) when P1-HNF4α2 was ectopically coexpressed with c-Src Y530F in HEK293 cells (Fig. 1C) ; P2-HNF4α8 yielded 6-fold less signal, despite equivalent recovery of the unphosphorylated peptide (Fig. S2I) . A Y277/Y279 peptide containing a single phospho group was also detected; sequencing of the peptide in three independent experiments indicated that the phosphorylation was on Y277, consistent with Y277 fitting the Src consensus site (DEEIYEEFF) better than Y279 (DNEY 277 AY 279 LK) (24) . Y14 and Y277 were further validated as Src sites in in vivo and in vitro assays using site-directed mutants and an Ab raised against phospho-Y14 (pY14) (Figs. 1D and Fig. S2 D and E) . Importantly, the phosphorylation signal is almost completely lost in all Y14F mutants, confirming that Y14 is critical for subsequent Srcmediated phosphorylation (Fig. 1D and Fig. S2F ). Interestingly, a Y279F mutant consistently yielded increased total pY as well as pY14, but only in the presence of PV (Fig. 1D, and Fig. S2J ). Indeed, in the absence of PV, the Y279F mutant resulted in reduced total pY and pY14 (Fig. S2J) , suggesting a dynamic relationship between Y279 and Y14 that may involve a phosphatase.
Phosphomimetic Mutants of P1-HNF4α Negatively Affect Protein
Function and Stability. Modeling of the HNF4α LBD shows that Y277 flanks a salt bridge between E150 (helix 1) and K281 (helix 8) (Fig. 2A, Top) that is part of a communication pathway linking the cofactor binding site to the dimer interface (25) . In contrast, Y279 is near a hydrophobic cavity at the dimer interface, pointing towards the interface of helix 9 and helix 1 ( Fig. 2A, Bottom) . Negatively charged groups at Y277 and Y279 are therefore predicted to adversely affect HNF4α protein dimerization and/or transactivation. The model also shows that Y277 and Y279 are too far apart (15.4 Å) for one kinase molecule to phosphorylate both in a single event (Fig. S3A ). This suggests that the phosphorylation of these residues may occur in a sequential fashion, a notion that is supported by the singly phosphorylated Y277 peptide detected by mass spectrometry.
To decipher the role of the three phosphorylated tyrosines, we examined the activity of single and double phosphomimetic mutants of Y14 (Y14E) and Y277/Y279 (Y277E/Y279E), respectively, and found that while Y14E had only a marginal effect on HNF4α2 transactivation (Fig. S3B) , the Y277E/Y279E double mutant completely abolished it (Fig. 2B) . Since the DNA binding activity of Y277E/Y279E was only marginally reduced compared to that of WT HNF4α2 (Fig. S3C) , we examined the intracellular localization of the double mutant and found a substantial cytoplasmic localization (Fig. 2C, and Fig. S3D ) that was reversed in the presence of nuclear export inhibitor leptomycin B (Fig. 2D) . However, neither leptomycin B nor increased amounts of expression vector (Fig. 2E ), or addition of the potent HNF4α coactivator PGC1α (Fig. 2F) , recovered the transactivation function of Y277E/Y279E. Lastly, we examined the protein stability of Y277E/Y279E and found it greatly reduced compared to WT or Y277F/Y279F ( Fig. 2G and Fig. S3E ). Taken together, these results indicate that Y277E/Y279E has reduced nuclear localization and protein stability. It also appears to have a reduced ability to recruit coactivators and decreased transactivation function, consistent with active Src decreasing the ability of WT HNF4α2 to activate transcription ( in an HEK293 cotransfection assay, while Src inhibitor PP2 increased HNF4α2 protein levels ( S4D ). We also show that endogenous P1-but not P2-HNF4α is phosphorylated in CaCo2 cells by both IP/IB (Fig. 3C ) and mass spectrometry; the latter showed that as much as 40% of the P1-HNF4α was doubly phosphorylated at Y277/ Y279 in CaCo2 cells (Fig. 3D ). Finally, a 24-h treatment of CaCo2 cells with Src inhibitor PP2 significantly decreased endogenous P1-HNF4α phosphorylation (Fig. 3E ) and increased the level of P1-HNF4α protein (Fig. 3F ). In contrast, there was a marked decrease in P2-HNF4α protein upon PP2 treatment, which could be due to the fact that P1-HNF4α is known to decrease transcription of the P2 promoter (21) . All told, selective phosphorylation of endogenous P1-HNF4α in a colon cancer cell line correlates with decreased protein stability and is consistent with the experiments using ectopic expression and phosphomimetic mutants.
Src SH2 and SH3 Domains Interact with P1-HNF4α. Since Src SH2 and SH3 domains (bind pY and proline-rich regions, respectively) are known to play a role in regulating Src activity and processive phosphorylation of its substrates, we examined their ability to interact with HNF4α. Not only did WT HNF4α2 phosphorylated by active Src bind the Src SH2 domain in vitro, but Y14 was required for maximal interaction (Fig. 4A, and Fig. S5B ). In contrast, P2-HNF4α8 did not bind Src SH2 appreciably (Fig. 4B) . To verify the specificity of the interaction, we showed that the Src SH2 mutant R178A does not interact with phospho-HNF4α2 (Fig. S5B) , and that the pY14 peptide binds directly to the WT Src SH2 domain, but not the R178A mutant (Fig. 4C) . We also found that the pY14 but not the nonphosphorylated (Y14) peptide can effectively compete with phospho-HNF4α2 for binding the Src SH2 domain (Fig. 4D) . Finally, using an in vivo kinase assay, we show that a WT Src SH2 domain is required for total tyrosine phosphorylation of HNF4α2 but is less important for Y14 phosphorylation (Fig. 4E) . These results are consistent with the notion that phosphorylation of Y14 is the first event and that the Src SH2 domain subsequently binds pY14. The results are Ab. Indicated is the fold difference in the phosphorylation signal with the Src SH2 mutant relative to c-Src Y530F at each ratio. Fold difference for the 1∶0.2 ratio was calculated using a darker exposure of the 4G10 blot. NA, not applicable as no signal was observed.
also of interest since Y14 (PApY 14 TTL) only partially fits the known consensus for a Src kinase substrate (pY(E/D/T)(E/N/Y) (L/I) ) and SH2 domain ligand [(P/H)(I/P)pY(E/D/V/I)(L/I/E) (I/L/V)] (24)
. Finally, to show that pY14 is required for phosphorylation of the LBD, we examined an N-terminally truncated HNF4α2 construct (ΔAB) and found that it was neither phosphorylated in vivo by active Src (Fig. S6A ) nor greatly repressed in transactivation function by Src compared to WT HNF4α2 (Fig. S6C) . These results confirm that the P1-driven A/B domain is actively required for the phosphorylation of the LBD.
Since the F domain of HNF4α is proline rich, we predicted and observed an interaction between WT HNF4α2 and the Src SH3 domain in a GST pulldown assay (Fig. 5A) . Interestingly, like the SH2 mutant, an SH3 mutant W121A decreased total HNF4α2 phosphorylation but had little effect on pY14 (Fig. 5B) . These results suggest that the Src SH3 domain, like the SH2 domain, is not required for Y14 phosphorylation but that it is required for phosphorylation of the LBD. Consistent with this notion, mass spectrometry did not show any phosphorylation on Y277 when HNF4α2 was cotransfected with the Src SH3 mutant (Fig. S5C) . Finally, a luciferase assay showed that while both the WT and c-Src Y530F decreased HNF4α2 transcriptional activity, the SH3 mutant W121A and, to a lesser extent the SH2 mutant R178A, exhibited less repression (Fig. S5D) . Taken together, these results show that HNF4α2 binds both the Src SH2 and SH3 domains and that those interactions play an important role in the isoformspecific phosphorylation of HNF4α.
SNPs in HNF4α Affect Src Phosphorylation and Protein Stability. There are three SNPs in human HNF4α that might be relevant to the interaction with Src (dbSNP, http://www.ncbi.nlm.nih.gov/ projects/SNP/). Introduction of mutations corresponding to two SNPs in the F domain (P421L, rs6031602, and P436S, rs1063239) dramatically decreased binding to the Src SH3 domain (Fig. 5A) . Rather unexpectedly, in the presence of cotransfected active Src, both variants (P421L and P436S) yielded a greater pY14 signal compared to WT HNF4α2 (Fig. 5C ), especially P421L. Another SNP adjacent to Y279 (L280F, rs6093980) also yielded a greater pY14 signal (Fig. 5C) . Importantly, all three SNPs (L280F, P421L, P436S) exhibited decreased protein stability compared to WT HNF4α2, but only in the presence of active Src (Fig. 5D and Fig. S6D ). Finally, two of the SNP variants (L280F and P421L) exhibited lower levels of transactivation than WT HNF4α2 in the absence of active Src, while the third variant P436S activated transcription as well as WT (Fig. 5E) . Importantly, all three variants were more susceptible to Src-mediated repression of transactivation than WT HNF4α2, even after normalizing to the amount of HNF4α protein (Fig. 5E ). This increased sensitivity of the SNP variants to Src is consistent with the increased phosphorylation observed in Fig. 5C .
The results thus far show that the proline-rich F domain of WT HNF4α2 interacts with the Src SH3 domain and that this interaction is required for full phosphorylation. However, the SNP variants show that the WT F domain may inhibit Src-mediated phosphorylation and repression of HNF4α2 transactivation. To address this apparent discrepancy, we examined the in vivo phosphorylation of HNF4α2 truncated in the F domain (ΔF). The results show that HNF4α ΔF is indeed phosphorylated by Src (Fig. S6A ). In addition, mass spectrometry of cotransfected HNF4α and active Src showed that the amount of the singly phosphorylated pY277 peptide (1431.2) was greater in ΔF than in WT HNF4α2 (41% vs 3.6%, respectively) (Fig. S6B) . Consistent with the notion that the F domain inhibits Src-mediated phosphorylation of HNF4α2, the ΔF truncation also exhibited a greater reduction in transactivation in the presence of active Src than did WT HNF4α2 (Fig. S6C) . Therefore, the F domain appears to play a modulatory role in Src-mediated effects on HNF4α2 via binding the SH3 domain.
Preferential Loss of Nuclear P1-HNF4α Correlates with Active Src Staining in Human Colon Cancer. In a pilot study of tumors from human patients with colon cancer, we found that only 26 out of 43 tumors were positive for a P1-HNF4α specific Ab (P1) while all 43 tumors showed staining with the Ab that recognizes both P1-and P2-HNF4α (P1/P2) ( Fig. S7 A and B) . This preferential loss of P1-HNF4α is consistent with previous results on a similarsized cohort of patients (22, 23) . Screening a larger cohort of 450 consecutive Stage III colon cancer cases revealed four categories of tumors when intensity of P1 staining was considered-loss of all P1 staining (a, approximately 12%); predominantly cytoplasmic P1 staining (b, approximately 18-24%); nuclear and cytoplasmic P1 staining (c, approximately 47-49%); and only nuclear P1 staining (d, approximately 18-23%) (Figs. 6 A-B, Fig. S7 C  and D) . All told, approximately 80% of tumor samples showed a P1-HNF4α staining that was not exclusively nuclear; in contrast, in normal tissue HNF4α staining was observed only in the nucleus (Figs. S7E and S8B) .
To assess the state of Src activation in the tumors, a subset of the samples (98 tissue microarray cores from invasive front and central regions of tumors) were stained with anti-phospho-Src antibody (pTyr 419, clone 9A6). The tumors showed a consistent staining for pSrc in the nucleus, especially when P1-HNF4α was either completely cytoplasmic or absent (Fig. 6C, sections I, II) . In contrast, when there was appreciable nuclear P1-HNF4α in the tumor area, there was low pSrc staining (sections III, IV). Furthermore, the adjacent normal tissue, which had essentially exclusive nuclear P1-HNF4α in nearly all the cells, showed little evidence of pSrc staining (Fig. S8C) . All told, the majority of the samples (Fig. S8C, categories 1 + 2 , 61 out of 98 tumor cores; X 2 ¼ 7.772, p ¼ 0.005) were consistent with the notion that activation of Src may result in cytoplasmic localization and/or complete loss of P1-HNF4α. Here we report that cytoplasmic P1-HNF4α staining in human colon cancer correlates with staining for active Src. While active Src is typically found in the cytoplasm and is tethered to the plasma membrane via a fatty acid anchor, there is a previous report of nuclear localization of pSrc in human colon cancer (26) . We have also observed nuclear pSrc in CaCo2 cells, as well as in three other human colon cancer cell lines (RKO, SW620, SW480) (Fig. S8D ).
Discussion
In this study, we identify HNF4α as a new target of Src kinase and in the process elucidate a complex interaction that has important ramifications for human colon cancer. We find that Src first phosphorylates Y14 in the N-terminal A/B domain of P1-HNF4α (Fig. 6D, Step 1) . Subsequently, pY14 binds the SH2 domain of Src and the proline-rich F domain of HNF4α binds the Src SH3 domain, thereby facilitating the phosphorylation of first Y277 and then Y279 in the HNF4α LBD (Step 2). We propose that this tethering of the Src protein brings its kinase domain in close proximity to the Y277/279 residues that are normally not very accessible. Since we have shown previously that the HNF4α F domain functions as a transcriptional repressor in part by interacting with the LBD (27) , we also propose that by binding the F domain, the Src SH3 domain disrupts the interaction with the LBD, thereby making Y277 and Y279 more accessible for phosphorylation. The net result is a triply phosphorylated HNF4α (Step 3) in which pY277 and pY279 evidently disrupt the coactivator binding site, resulting in a loss of transactivation, nuclear localization, and protein stability. We also show that three SNPs in HNF4α (L280F, P421L, and P436S) increase Src-mediated phosphorylation, degradation of HNF4α protein and repression of transcription. Therefore, we propose that while the SNP variants in the F domain disrupt the interaction with the Src SH3 domain, they also abrogate the interaction of the F domain with the LBD, thereby at least partially exposing Y277 and Y279 (Fig. 6E) . What is not clear, however, is exactly how the SNPs lead to increased phosphorylation of Y14. Importantly, this entire sequence of events happens only on P1-HNF4α as P2-HNF4α does not contain Y14. Since P2-HNF4α8 has the same F domain as P1-HNF4α2, this (and other experiments presented in this work) indicates that the binding of the Src SH3 domain to HNF4α alone is not sufficient to cause substantial phosphorylation of HNF4α. As we observed in the human colon cancer samples, the net result is a preferential loss of P1-but not P2-HNF4α under conditions that activate c-Src, or a Src kinase family member (the pSrc antibody recognizes the pY419 of several different Src family kinase members). Furthermore, there appears to be a negative effect of Src on HNF4α-mediated transactivation, even when reduced HNF4α protein levels are taken into account. This suggests that any phospho-HNF4α protein remaining in the nucleus may also have reduced transcriptional activity.
While a few other nuclear receptors are known to be phosphorylated by Src kinase (28-30), here we report the isoformspecific phosphorylation of a nuclear receptor by Src kinase. We also provide evidence suggesting that SNP variants in a nuclear receptor may increase one's susceptibility to c-Src, and hence to Src-mediated cancer. Finally, the interaction between Src kinase and HNF4α described here may also be relevant in other cancers, such as hepatocellular carcinoma, which has been shown to have high levels of active Src (31) and a loss of P1-driven HNF4α (22) .
Materials and Methods
Src Kinase Assays. In vitro kinase assays were performed as per the manufacturer's protocol (Millipore) using recombinant active Src (25-50 ng), 32 P-γ-ATP and purified GST fusion proteins or human HNF4α [wild type (WT) or mutant] immunoprecipitated (IP'd) from transfected HEK293 cells. In vivo kinase assays used HEK293 or COS-7 cells transfected with HNF4α and c-Src Y530F treated with 100 μM PV for 3-30 min before lysing with RIPA buffer as indicated. HNF4α was IP'd with the affinity purified Ab α445 and then eluted with 445 peptide. In vivo phosphorylation assays in CaCo2 cells were performed with cells at <50% confluency; whole cell extracts were IP'd with either α445 Ab (and peptide eluted) or 4G10 platinum Ab (Millipore). All reaction products were analyzed by 10% SDS-PAGE followed by autoradiography or immunoblot (IB) analysis. All Src kinase assays were performed three or more times.
Human Colonic Adenocarcinoma Tissue Staining. Patients had a surgical resection for Australian Clinicopathological Stage III colonic adenocarcinoma, equivalent to TNM Stage III (32, 33) but were excluded if they had a history of ulcerative colitis (UC) or Crohn's disease or if UC, Crohn's disease, or polyposis coli was detected in the surgical specimen. Tissue microarrays (TMAs) were constructed with 1.0 mm cores from morphologically representative areas of the original archived paraffin blocks (the central region of the tumor, deep advancing tumor front, and adjacent nonneoplastic mucosa) using an Advanced Tissue Arrayer, ATA-100 (Chemicon). HNF4α immunoreactivity in each tissue core was assessed independently by L.J. and two experienced pathologists (C.L-S.F., C.C.) for staining intensity (0 ¼ absent, 1 ¼ weak, 2 ¼ intermediate, 3 ¼ strong staining) using P1-specific and P1/P2 antibodies as previously described (34) . pSrc (pTyr419) immunoreactivity was similarly determined. Approval for this study incorporating informed consent was obtained from the South Western Sydney Area Health Service.
